A phase I trial of ATN-249 to evaluate safety, tolerability and pharmacokinetic profile in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2017
At a glance
- Drugs ATN 249 (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Pharmacokinetics
- 09 Mar 2017 New trial record
- 07 Mar 2017 Acording to Attune Pharmaceuticals media release, company expects to start the trial in middle of 2017.